Polianta Ltd’s Madrigal Pharmaceuticals MDGL Stock Holding History

Polianta Ltd’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,300	Closed	-$1.04M	–	87
2023 Q1	$1.04M	Buy	+4,300	New	+$1.17M	0.48%	55

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Polianta Ltd's MDGL Position: Q2 2023 in Review

Polianta Ltd sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 4,300 shares — an estimated $1.04M sold.

Polianta Ltd first reported a position in MDGL in Q1 2023 and held it in 1 quarter. The position peaked at $1.04M in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

Polianta Ltd reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Polianta Ltd sold 4,300 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $1.04M.
Polianta Ltd first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Polianta Ltd's Madrigal Pharmaceuticals position peaked at $1.04M in Q1 2023.
208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Polianta Ltd's 13F filing for Q2 2023, filed 19 Jul 2023.